EMD Serono to Adopt Revised and Strengthened PhRMA Code - Revised Code Demonstrates Strong Commitment to Ethical Information Exchange between Physician Community and Leading Biotechnology and Pharmaceutical Companies - ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc.announced today...
EMD Serono to Adopt Revised and Strengthened PhRMA Code ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc.announced today that the company has adopted and will fully implement, the revised and strengthened PhRMA Code on Interactions with Healthcare Professionals.
The revised voluntary...
EMD Serono to Adopt Revised and Strengthened PhRMA Code ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc.announced today that the company has adopted and will fully implement, the revised and strengthened PhRMA Code on Interactions with Healthcare Professionals.
The revised voluntary...
EMD Serono to Adopt Revised and Strengthened PhRMA Code ROCKLAND, Mass., July 10 /PRNewswire/ -- EMD Serono, Inc.announced today that the company has adopted and will fully implement, the revised and strengthened PhRMA Code on Interactions with Healthcare Professionals.
The revised voluntary...
EMEA Confirms Positive Benefit-Risk Balance With Raptiva(R) for the Treatment of Psoriasis - European Commission Approved Product Information Update to Include Data on up to Three Years of Treatment With Raptiva(R), the Longest for any Approved Biological Therapy for Psoriasis GENEVA, Switzerland, July 1 /PRNewswire/ -- Merck...
Merck Serono and Bionomics Announce Multiple Sclerosis Development and - Bionomics (News) and Merck Serono (News/Aktienkurs) to Collaborate to Discover and Develop Novel, Oral Treatment for MS - Collaboration Based on Novel Compounds That Allow Selective Inhibition of The Immune Cells Which Cause Nerve Cell...
Merck Serono and Bionomics Announce Multiple Sclerosis Development and Licensing Agreement - Bionomics and Merck Serono to Collaborate to Discover and Develop Novel, Oral Treatment for MS - Collaboration Based on Novel Compounds That Allow Selective Inhibition of The Immune Cells Which Cause Nerve Cell Damage in Patients With MS...
Merck Serono Strengthens its Prescription Medicines Portfolio in Latin - Merck Serono (News/Aktienkurs) to Commercialize Portfolio of Established Pharmaceutical Medicines From Bristol-Myers Squibb in Latin America Merck Serono (NYSE: SRA), a division of Merck KGaA, Darmstadt, Germany, announced today the...
Merck Serono's Rebif(R) Celebrates 10th Anniversary - A Decade Dedicated to Helping People With Multiple Sclerosis - Extensive Research and Development Activities Underscore Long-Term Commitment to Improving the Lives of People With Multiple Sclerosis Merck's Serono's Rebif(R) (interferon...
Merck Serono Announces Initiation of Second Phase II/III Clinical Study of Atacicept in Lupus - Trial in Systemic Lupus Erythematosus (SLE) Intended to Form Part of Potential Registration Package GENEVA, Switzerland, June 5 /PRNewswire/ -- Merck Serono, a division of Merck KGaA, Darmstadt, Germany, and its development partner...
Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer - New Data Provides the Basis for the Future Role of Erbitux (cetuximab) as a Standard in Combination With Platinum-Based Chemotherapy in the 1st-Line Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) - Location: Annual Meeting...
Unique Three-Year Data Demonstrating Long-Term Efficacy and Safety of Raptiva in the Treatment of Psoriasis Pu Longest continuous-treatment prospective study of a biological therapy for psoriasis GENEVA, Switzerland, May 5, 2008 Final results of the first three-year prospective efficacy and safety study in moderate-to-severe chronic plaque psoriasis...
